2018
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 102-109. PMID: 28991888, PMCID: PMC5720915, DOI: 10.1097/qai.0000000000001562.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS Dementia ComplexAIDS-Related Opportunistic InfectionsAlkynesAmericasAtazanavir SulfateBenzoxazinesCohort StudiesCyclopropanesDarunavirEuropeFemaleHIV Protease InhibitorsHumansLeukoencephalopathy, Progressive MultifocalLopinavirMaleMeningitis, CryptococcalMiddle AgedProspective StudiesReverse Transcriptase InhibitorsToxoplasmosisConceptsNucleoside reverse transcriptase inhibitor (NRTI) backboneReverse transcriptase inhibitor backboneHazard ratioNeurological conditionsInhibitor backbonePooled logistic modelCombined end pointRespective hazard ratiosProgressive multifocal leukoencephalopathyProspective cohort studyAntiretroviral therapy regimensHIV-positive individualsHIV-CAUSAL CollaborationIncidence of AIDSCART initiationHIV dementiaAntiretroviral therapyCART regimenCryptococcal meningitisMultifocal leukoencephalopathyClinical characteristicsCohort studyTherapy regimensAtazanavirLopinavir
2016
Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality
Salinas JL, Rentsch C, Marconi VC, Tate J, Budoff M, Butt AA, Freiberg MS, Gibert CL, Goetz MB, Leaf D, Rodriguez-Barradas MC, Justice AC, Rimland D. Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. Clinical Infectious Diseases 2016, 63: 1423-1430. PMID: 27539575, PMCID: PMC5106607, DOI: 10.1093/cid/ciw564.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIncident acute myocardial infarctionVeterans Aging Cohort StudyCombination antiretroviral therapyCardiovascular risk factorsHIV-1 RNAVACS IndexHazard ratioMyocardial infarctionRisk factorsMultivariable proportional hazards modelsVACS Index scoreLast clinic visitAging Cohort StudyHuman immunodeficiency virusProportional hazards modelCART initiationAntiretroviral therapyCause mortalityCD4 countClinic visitsCohort studyOrgan injuryPrimary outcomeImmunodeficiency virus
2015
Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US
Jarrin I, Moreno S, Ingle S, May M, Sterling T, Justice A, Bickel M, Crane H, Mugavero M, De Wolf F, Jung N, Cescon A, Garcia I, Elzi L, Arminio A, Krause M, Smith C, Guest J, Hessamfar M, Gill J, Sterne J, del Amo J. Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US. Antiviral Therapy 2015, 20: 21-28. PMID: 24675571, DOI: 10.3851/imp2768.Peer-Reviewed Original ResearchConceptsNon-AIDS mortalityInjection drug useAll-causeAntiretroviral therapyAIDS-mortality rateNon-AIDS-related mortalityCause-specific mortalityCD4(+) T-cell countsNon-AIDS infectionsRates of all-causeNon-AIDS malignanciesART Cohort CollaborationT-cell countsHIV-infected adultsHIV-positive patientsHIV-1 RNAAll-cause mortalityCox proportional hazards modelsCohort of individualsHIV-positive menProportional hazards modelART-CCSex differencesCART initiationCause-specific
2014
Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, EuroCoord F, Engsig F, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla P, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher H, De Wit S, Burkholder G, Teira R, Justice A, Sterling T, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle S, Sterne J, Boulle A, Brodt H, Casabona J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Mocroft A, Obel N, Kitahata M, Lampe F, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Ingle S, May M, Sterne J, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause M, Ghosn J, Leport C, Reiss P, Wit F, Prins M, Bucher H, Sabin C, Gibb D, Fätkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Pérez-Hoyos S, Hamouda O, Gussenheimer-Bartmeyer B, Noguera-Julian A, Antinori A, Monforte A, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Miró J, Castagna A, de Wit S, Goetghebuer T, Torti C, Teira R, Garrido M, Judd A, Conejo P, Haerry D, Weller I, Casabona J, Costagliola D, d'Arminio-Monforte A, Battegay M, de Wit S, Del Amo J, Grarup J, Chêne G, Colin C, Schwimmer C, Termote M, Kjaer J, Campbell M, Raben D, Battegay M, Bohlius J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dabis F, Monforte A, del Amo J, Dorrucci M, Egger M, Engsig F, Furrer H, Judd A, Kirk O, Lambotte O, Lewden C, Lodi S, Lodwick R, Matheron S, Meyer L, Miro J, Mocroft A, Monge S, Nakagawa F, Obel N, Paredes R, Phillips A, Puoti M, Reekie J, Sabin C, Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, Touloumi G, Wittkop L. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases 2014, 58: 1312-1321. PMID: 24457342, PMCID: PMC6276895, DOI: 10.1093/cid/ciu038.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyIncomplete CD4 recoveryCD4 countLong-term mortalityHIV-positive individualsViral suppressionRisk factorsCD4 recoveryInitiation of cARTLow initial CD4 countsCD4 cell recoveryLow CD4 countSustained viral suppressionInitial CD4 countHuman immunodeficiency virusCause of deathDifferent patient groupsCART initiationAntiretroviral therapyHIV cohortCox regressionImmunodeficiency virusPatient groupEligible individualsSubsequent mortality
2012
Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases 2012, 54: 1364-1372. PMID: 22460971, PMCID: PMC3404691, DOI: 10.1093/cid/cis203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDeveloped CountriesDrug Therapy, CombinationEuropeFemaleHIV InfectionsHIV SeropositivityHumansImmune Reconstitution Inflammatory SyndromeIncidenceMaleMiddle AgedMycobacterium tuberculosisPneumocystis cariniiPneumonia, PneumocystisRNA, ViralTuberculosisUnited StatesViral LoadConceptsImmune reconstitution inflammatory syndromeCD4 cell countCells/μL.HIV RNA levelsHazard ratioTuberculosis incidenceCART initiationCell countAntiretroviral therapyTime-varying CD4 cell countBaseline CD4 cell countAIDS-free individualsEffects of CARTLow tuberculosis incidenceMonths of ARTReconstitution inflammatory syndromeHIV-positive patientsRNA levelsHIV-positive individualsHuman immunodeficiency virusHIV-CAUSAL CollaborationInflammatory syndromeImmunodeficiency virusInverse probability weightingPositive individuals
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosisWhen to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher H, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan M. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals Of Internal Medicine 2011, 154: 509-15. PMID: 21502648, PMCID: PMC3610527, DOI: 10.7326/0003-4819-154-8-201104190-00001.Peer-Reviewed Original ResearchConceptsCD4 cell countCombined end pointHazard ratioCell countCells/LAntiretroviral therapyCells/L.CD4 cell count thresholdBaseline CD4 cell countEnd pointVeterans Health Administration systemInitiation of cARTThreshold CD4 countCorresponding hazard ratiosMortality hazard ratioAIDS-free survivalProspective observational dataHIV-CAUSAL CollaborationMost clinical guidelinesHealth Administration systemUse of CD4Marginal structural modelsCell count thresholdCART initiationDynamic marginal structural models
2010
Rural Residence Is Associated With Delayed Care Entry and Increased Mortality Among Veterans With Human Immunodeficiency Virus Infection
Ohl M, Tate J, Duggal M, Skanderson M, Scotch M, Kaboli P, Vaughan-Sarrazin M, Justice A. Rural Residence Is Associated With Delayed Care Entry and Increased Mortality Among Veterans With Human Immunodeficiency Virus Infection. Medical Care 2010, 48: 1064-1070. PMID: 20966783, PMCID: PMC3138500, DOI: 10.1097/mlr.0b013e3181ef60c2.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesConfidence IntervalsFemaleHealth Services AccessibilityHIV InfectionsHumansMaleOdds RatioPatient Acceptance of Health CareRetrospective StudiesRisk AssessmentRural Health ServicesRural PopulationSeverity of Illness IndexSurveys and QuestionnairesSurvival AnalysisUnited StatesUrban PopulationVeteransConceptsHuman immunodeficiency virusRural residenceCare entryHazard ratioHIV outcomesHIV severityRural personsVeterans AdministrationCombination antiretroviral therapy useHuman immunodeficiency virus (HIV) infectionRural-Urban Commuting Area codesAdvanced HIV infectionAntiretroviral therapy useRetrospective cohort studyImmunodeficiency virus infectionMortality hazard ratioCommunity-level determinantsRural-urban variationDrug use problemsCART initiationCause mortalityHepatitis CCohort studyHepatitis BHIV infection
2009
Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA. Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 52: 357-363. PMID: 19668084, PMCID: PMC3032437, DOI: 10.1097/qai.0b013e3181b62933.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countBaseline CD4 countCD4 countImmunologic responseVirologic suppressionCell countAntiretroviral therapyAbsolute CD4Absolute CD4 cell countCD4 cell count strataAdequate immunologic responseART Cohort CollaborationClear therapeutic goalsTreatment-naive individualsCell count strataCART initiationCohort CollaborationCD4 changeHazard ratioViral loadEligible participantsSubsequent prognosisClinical significancePrognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte A, Force L, Gill J, Harris R, Hogg R, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne J, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23: 2199-2208. PMID: 19779320, PMCID: PMC3122149, DOI: 10.1097/qad.0b013e3283305a00.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countHIV-1-infected patientsHIV-1 RNAViral loadCART initiationCell countStart of cARTHIV-1 RNA measurementsART Cohort CollaborationMedian CD4 cellPredictors of AIDSRates of AIDSImportant prognostic factorPrognosis of patientsCohort CollaborationSubsequent AIDSAntiretroviral therapyHIV cohortCD4 cellsPrognostic factorsPrognostic importanceCopies/PatientsAIDS
2008
Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV
Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV. Value In Health 2008, 11: 975-979. PMID: 18225989, PMCID: PMC3121315, DOI: 10.1111/j.1524-4733.2007.00315.x.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyBothersome symptomsSF-6D utilitiesAntiretroviral therapyCD4 countSide effectsVeterans Aging Cohort StudyAging Cohort StudySF-12 scoresAfrican American raceHazardous alcohol consumptionQuality of lifeRecent drug useCART initiationMild anginaCohort studyMultivariable analysisCigarette smokingUnivariate analysisAmerican raceAlcohol consumptionDrug useUtility decrementsPatientsClinical decision